Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Travoprost in open-angle glaucoma or ocular hypertension
NCT00293761Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jan 2006
- Primary completion
- May 2006
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of travoprost in Open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Alcon Inc. Primary endpoint: Intraocular Pressure at 13 days. Started Jan 2006; status: completed.
02
Drugs
travoprost
03
Conditions
Open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00293761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293761.